VOR - Dividend announcements

Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO on track for IND submission in first half of 2023$116M financing extends expected cash runway into Q1 2025 CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2022, and provided a business update.  "We are encouraged with the initial proof of concept demonstrated in patients treated in our VBP101 study," said Dr. Robert Ang,

Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2022 and provided a business update.  "We continue to actively enroll patients in our lead clinical trial, VBP101 and look forward to sharing important initial clinical proof of concept data from this study by year end," said Dr. Robert Ang, Vor Bio's President and Chief Executive Officer. "We are excited tha

Initial clinical data for patients treated with Vor Bio's engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at EHA successfully demonstrates in-vivo engraftment of multiplex edited HSCs for next-generation AML treatmentCash runway extended into Q1 2024 CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2022, and provided a business update.  "We are on track to disclose first-in-human clinical data for our lead product candidate VOR33 in Q4 this year,"

Initial clinical data for Vor Bio's engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing platformIn-house manufacturing facility in Cambridge, MA operational in 2022 CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2022, and provided a business update.  "We remain fully focused on generating first-in-human clinical data from VBP101, our Phase 1/2a clinical trial of VOR33 in patients with relapsed/refractory AML, which will provide important

Initial clinical data for Vor Bio's engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended into Q4 2023 providing additional financial flexibility and optionality CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2021, and provided a business update.  "2022 is a pivotal year for Vor Bio with a number of catalysts that will continue to validate the potential of our platform," said Dr. Robert Ang, Vor Bio's Presid

VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2021, and provided a business update.  "Our main focus during the third quarter of 2021 has been on site activation and patient recruitment in the Phase 1/2a trial of VOR33 for patients with AML. The initial data from this trial, expected in the first half of 2022, is intended to provi